Pathogenic mutations with AF of >20 were regarded as driver mutations, and 89.5% of patients with lung cancer were found to harbor driver mutations in EGFR, KRAS, or TP53, which were found to be the three major mutations in lung cancer. Here, TP53 is linked to lung carcinoma.